These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 23342871)
41. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis]. Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669 [TBL] [Abstract][Full Text] [Related]
43. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Srivastava MD; Alexander F; Tuthill RJ Scand J Immunol; 2005 Apr; 61(4):329-36. PubMed ID: 15853915 [TBL] [Abstract][Full Text] [Related]
44. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis. Nell-Duxneuner V; Schroeder Y; Reichardt B; Bucsics A Int J Clin Pharmacol Ther; 2012 Dec; 50(12):867-72. PubMed ID: 23036238 [TBL] [Abstract][Full Text] [Related]
45. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543 [TBL] [Abstract][Full Text] [Related]
46. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743 [TBL] [Abstract][Full Text] [Related]
51. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept]. Breedveld FC Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851 [TBL] [Abstract][Full Text] [Related]
52. New biologic agents: a critical appraisal. Sands BE Curr Gastroenterol Rep; 1999 Dec; 1(6):470-5. PubMed ID: 10980988 [TBL] [Abstract][Full Text] [Related]
53. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. de Vries MK; van der Horst-Bruinsma IE; Nurmohamed MT; Aarden LA; Stapel SO; Peters MJ; van Denderen JC; Dijkmans BA; Wolbink GJ Ann Rheum Dis; 2009 Apr; 68(4):531-5. PubMed ID: 18375542 [TBL] [Abstract][Full Text] [Related]
54. Crohn's disease in patients treated with etanercept. Valdivielso Cortázar E; Diz-Lois Palomares MT; Alonso Aguirre P Rev Esp Enferm Dig; 2020 Jan; 112(1):80-81. PubMed ID: 31793319 [TBL] [Abstract][Full Text] [Related]